A multi-center study on the regenerative effects of erythropoietin in burn and scalding injuries: study protocol for a randomized controlled trial
Authors:
- Augustinus BaderABAugustinus Bader
- Ulf DornseiferUDUlf Dornseifer
- Silvia EgertSESilvia Egert
- Sebastian DundaSDSebastian Dunda
- Gerrit GriebGGGerrit Grieb
- Thomas WolterTWThomas Wolter
- Norbert PalluaNPNorbert Pallua
- Tobias von WildTWTobias von Wild
- Frank SiemersFSFrank Siemers
- Oliver ThammOTOliver Thamm
- Carsten ErnertCECarsten Ernert
- Michael SteenMSMichael Steen
Open Access
- 1 January 2013
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 14 (1) , 1-8
Abstract
Although it was initially assumed that erythropoietin (EPO) was a hormone that only affected erythropoiesis, it has now been proposed that EPO plays an additional key role in the regulation of acute and chronic tissue damage. Via the inhibition of inflammatory reactions and of apoptosis, stem cell recruitment, advancement of angiogenesis and growth factor release, EPO enhances healing and thus restitutio ad integrum after trauma. Human skin contains EPO receptors and is able to synthesize EPO. We therefore hypothesize that EPO is able to optimize wound healing in thermally injured patients. This is a large, prospective, randomized, double-blind, multi-center study, funded by the German Federal Ministry of Education and Research, and fully approved by the designated ethics committee. The trial, which is to investigate the effects of EPO in severely burned patients, is in its recruitment phase and is being carried out in 13 German burn care centers. A total of 150 patients are to be enrolled to receive study medication every other day for 21 days (EPO 150 IU/kg body weight or placebo). A follow-up of one year is planned. The primary endpoint of this study is the time until complete re-epithelialization of a defined skin graft donor site is reached. Furthermore, clinical parameters such as wound healing, scar formation (using the Vancouver scar scale), laboratory values, quality of life (SF-36), angiogenic effects, and gene- and protein-expression patterns are to be determined. The results will be carefully evaluated for gender differences. We are seeking new insights into the mechanisms of wound healing in thermally injured patients and more detailed information about the role EPO plays, specifically in these complex interactions. We additionally expect that the biomimetic effects of EPO will be useful in the treatment of acute thermal dermal injuries. EudraCT Number: 2006-002886-38, Protocol Number: 0506, ISRCT Number: http://controlled-trials.com/ISRCTN95777824/ISRCTN95777824.Keywords
This publication has 37 references indexed in Scilit:
- Erythropoietin-induced upregulation of endothelial nitric oxide synthase but not vascular endothelial growth factor prevents musculocutaneous tissue from ischemic damageLaboratory Investigation, 2010
- Effects of erythropoietin in skin wound healing are dose relatedThe FASEB Journal, 2009
- Erythropoietin Protects Critically Perfused Flap TissueAnnals of Surgery, 2008
- Autocrine function of erythropoietin in IGF-1-induced erythropoietin biosynthesisNeuroReport, 2008
- Erythropoietin‐mediated tissue protection: reducing collateral damage from the primary injury responseJournal of Internal Medicine, 2008
- Attenuation of monocyte proinflammatory cytokine responses toNeisseria meningitidisin children by erythropoietinClinical and Experimental Immunology, 2008
- Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cellsPeptides, 2008
- Efficacy and Safety of Epoetin Alfa in Critically Ill PatientsNew England Journal of Medicine, 2007
- Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietinThe FASEB Journal, 2007
- EPO tecting the EndotheliumBritish Journal of Pharmacology, 2007